Ponatinib versus imatinib monotherapy after combination with chemotherapy in newly diagnosed Ph+ ALL скачать в хорошем качестве

Ponatinib versus imatinib monotherapy after combination with chemotherapy in newly diagnosed Ph+ ALL

Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, comments on the findings of a post-hoc subgroup analysis of the Phase III PhALLCON study (NCT03589326). This analysis highlighted that patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with ponatinib monotherapy after combination with chemotherapy had a significantly higher likelihood of continuing with long-term maintenance compared to those patients receiving imatinib. This suggests that ponatinib's efficacy extends beyond short-term benefits, potentially making it a more effective first-line treatment than imatinib when administered as monotherapy following combination with attenuated chemotherapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.